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Abstract 
Background: Discussion has continued concerning calorie restriction (CR) and low carbohydrate diet (LCD). LCD was 
developed by Bernstein, Atkins and others, and by our co-authors in Japan. In this study, we report and discuss long-term 
effects in 2,699 cases, and short-term effects and hyperketonemia in 51 cases.  
Subjects and Methods: Study 1 (long-term): Subjects were 2,699 cases with diabetes, metabolic syndrome, or both. Methods
included continuing LCD and measuring weight reduction in six to twelve months. Study 2 (short-term): Twenty-four 
diabetics were compared on a CR diet (1,400 kcal/day, carbo-60%) and a super-LCD (1,400 kcal/day, carbo-12%). We 
recently tried insulinogenic index-carbo70 (IGI-carbo70) from glucose and immunoreactive insulin (IRI; 0, 30 min) for a 
meal of carbohydrates of 70 g. Study 3 (hyperketonemia): Blood ketone bodies and 3-hydroxybutylic acid (3-OHBA) were 
measured in 51 diabetics with super-LCDs.  
Results: Study 1: Weight reduction of more than 10 % was observed in 25.6% of subjects, and more than 2.5% was 
observed in 78.8% of subjects. Study 2: Base data included HbA1c 7.7 ± 1.4 %, homeostasis model assessment (HOMA)-R 3.2 
± 1.9, and HOMA-β 44.5 ± 37.0. Responses of blood glucose to meals (0-120 min) were 156 → 236 mg/dL to CR and 116 
→ 141 mg/dL to LCD for ten days. Triglyceride value decreased from 143.4 ± 86.8 mg/dL to 93.9 ± 34.8 mg/dL on LCD 
for ten days. IGI-carbo70 showed less than 0.5 in 75% of cases. Study3: Total ketone bodies were measured in four groups, 
which were A (4 to 5 days), B (7 to 9 days), C (11 to 13 days), D (21 to 28 days), with an average value of 994 μmol/mL in 
C, 36 to 623 μmol/mL in A, B, and D. As 3-OHBA value increases from normal (<85 μmol/mL) to extremely high (3,577 
μmol/mL), the ratio increases from 60% - 70% up to 90%.
Conclusion: Long-term effects of LCD would be successful. Short-term effects revealed that the change from CR to LCD 
in only ten days caused a significant decrease of blood glucose and triglycerides. Similar to the 75 g oral glucose tolerance 
test (OGTT), intake of a meal with carbohydrates of 70 g would be clinically simple and useful as insulinogenic index 
(IGI)-carbo70. Super-LCD would increase blood ketone bodies about three fold of the standard level in four to five days. 
These findings would be the fundamental data in the LCD area and contribute the research of glycative changes.
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Introduction 
Metabolic syndrome such as obesity and diabetes mellitus
has recently increased, and Calorie Restriction (CR) and low 
carbohydrate diets (LCD) have been noted in medical and 
health fields. In Europe and the United States, Bernstein, 
Atkins and others 1, 2) have developed LCD, which has been 
wide spread 3-8).
In Japan, the coauthors have successfully treated 
thousands of patients with obesity, metabolic syndrome and 
other diseases 9-12). Ebe K first started in Japan in 1999 with 
many books, and Bando H developed this movement with 
medical presentations. We have developed a clinical study 
and research of LCD 13). 
From our clinical experiences, we report 1) long-term 
effects of LCD on 2,699 cases, 2) short-term effects of 
LCD, and 3) hyperketonemia due to LCD. This report would 
contribute the pathophysiological role of ketone bodies 
and glucose to glycative changes in patients with diabetes 
mellitus and obesity.
Subjects and Methods
Study 1: Long effects of LCD   
The subjects included 2,699 cases which were obese 
patients associated with diabetes, metabolic syndrome, or 
both. Methods included the treatment of a low carbohydrate 
diet for the patients, and we compared body weight before 
and after treatment; about six to twelve months at a stable 
weight. 
Study 2: Short-term effects of LCD   
 Subjects included 24 patients with diabetes mellitus. 
Ten were male, 14 female; with an average age of 61.6 ± 9.7 
years, median of 62.5 years, and a range of 40 to 78 years. 
They were admitted for further evaluation and treatment 
for 12 to 14 days, in which they had the same protocol for 
endocrine and metabolic examination. As for diet therapy, 
they were on a conventional calorie restriction (CR) from 
zero to two days, and a low carbohydrate diet (LCD) from 
three to 14 days. The former (CR) had 1,400 kcal/day, a 60 
% calorie ratio from carbohydrates, with a breakfast of 450 
kcal, 70 g of carbohydrates. The latter (LCD) (super LCD 
formula by Ebe) had 1,400 kcal/day, (breakfast 400 kcal, 
lunch 450 kcal, supper 550 kcal), a 12% calorie ratio from 
carbohydrates, with a breakfast of 400 kcal, and 12 g of 
carbohydrates.
1) On admission, the patients had fundamental tests including
blood glucose, HbA1c, immunoreactive insulin (IRI) and 
triglyceride (TG) associated with calculating a homeostasis 
model assessment (HOMA)-R and HOMA-β, and had 
measured TG value on day 12.
2) Blood glucose (0, 30, 120 min.)and IRI values (0, 30 min)
for breakfast on CR (day 2), and glucose values (0, 120 min)
for breakfast on LCD (day 12) were investigated. We calculated
the increment of IRI (0 to 30 min)/increment of glucose (0 - 
30min) for insulinogenic index-carbo70 (IGI-carbo70).
3) The concentration and components of blood ketone 
bodies were measured at four to five days (group A), seven 
to nine days (group B) and 11 to 13 days (group C). These 
data were inserted into Study 3.
Study 3: Elevated ketone bodies on LCD   
We included 51 subjects with continuing LCD treatment.
Twenty-one were male, 30 female, the average age was 59.5 
± 9.6 years, median age of 61.5 years, and a range of 34 
to 78 years. They had continued super-LCD meals, which 
include 12% of carbohydrates in calories. 
As ketone bodies, 3-hydroxybutylic acid (3-OHBA, 
β-hydroxybutylic acid) and acetoacetic acid (AcAc, 
acetoacetate) values were measured. In a clinical setting, 
a ketone bodies usually meant the value of 3-OHBA, and 
its standard range of 3-OHBA was less than 85 μmol/mL. 
The cases were classified into four groups according to the 
continuing days for LCD, in which group A was for four to 
five days, group B was for seven to nine days, group C was 
for 11 to 13 days and group D was 21 to 28 days. . 
Statistical analysis   
Data were shown as the mean ± standard deviation. As 
for the analysis of two groups, a t-test and Mann-Whitney 
U-test were used, and the Spearman method was adopted 
from the correlation of ketone body study. We used JMP 
(Version 8) statistical analysis software (JMP Japan Division 
of SAS Institute Japan Ltd., Minato-ku, Tokyo, Japan) and 
the Microsoft Excel analytical tool with a four step method. 
A significance level of less than 5% was obtained using the 
two-tailed test and was considered to indicate a significant 
difference. 
Ethical considerations   
 The present study was conducted in compliance with 
the ethical principles of the Declaration of Helsinki and 
Japan’s Act on the Protection of Personal Information, 
and with reference to the Ministerial Ordinance on Good 
Clinical Practice (GCP) for Drug (Ordinance of Ministry of 
Health and Welfare No. 28 of March 27, 1997). No ethics 
committee meeting was held. We obtained the informed 
consent from subjects concerning this questionnaire.
Results
Study1 showed the weight reduction rate in 2,699 cases, 
in which 567 subjects (21.2%) had weight reduction of 2.5% 
to 4.9%, 854 (32.0%) reduced 5.0% to 9.9%, 683 (25.6 
%) reduced 10% and more than 10% (Fig. 1). Thus, 2,104 
subjects (78.8%) showed weight reduction of 2.5% and 
more than 2.5%.  
Study2 showed the following data.
1) Fundamental data on admission is in Table 1, and the data 
of HOMA-R and HOMA-β are in Fig. 2, in which 18, and 
six cases in 24 cases, respectively, showed ranges outside of 
the normal ranges.
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2) Blood glucose values of zero and 120 min on day two 
(CR) and day12 (LCD) were shown in Fig. 3, in which the 
value of the latter was decreased from the former.  
Serum levels of triglyceride (TG) were measured on 
day two with CR, and day 12 with LCD, and showed 143.4 
± 86.8 mg/dL, and 110.3 ± 69.3 mg/dL, respectively, with a 
significant difference (p<0.05, n = 22) (Fig. 4). These data 
were calculated without two cases with extremely high TG 
values on day two.
3) The values of blood glucose and IRI (0, 30 min) were 
increased in response to breakfast of CR including 70 g 
of carbohydrate (Fig. 5). Simultaneously, we have recently 
tried to calculate for insulinogenic index (IGI) for 70 g of 
carbohydrates, similar to the 75 g oral glucose tolerance test 
(OGTT) and the insulinogenic index (Fig. 6). They showed 
less than 0.5 in 75% of the cases.
4) Several correlations among multiple markers were shown 
in Fig. 7. HbA1c values had a significant negative correlation
Fig. 1. Weight reduction rate in 2,699 cases. 
Five hundred sixty-seven subjects (21.2 %) had a weight reduction of 2.5 % to 4.9 %, 854 (32.0 %) had 5.0 % to 9.9 %, 
683 (25.6  %) had 10 % and more than 10 %. Thus, 2,104 subjects (78.8 %) showed weight reduction of 2.5 % and more 
than 2.5 %.  
with HOMA-β, and not a significant correlation with HOMA-R
(Figs. 7a, b). IRI values had a significant negative correlation
with fasting glucose, and a positive correlation with HOMA-β
(Figs. 7c, d). IRI increments for 70 g of carbohydrates showed
significant positive correlation with HOMA-β, and not a
significant correlation with HOMA-R (Figs. 7e, f ). In contrast,
the IRI value in 30 minutes had a significant correlation 
with both HOMA-R and HOMA-β (Figs. 7g, h).   
As for Study3, the value of blood ketone bodies (3-OHBA
+ AcAc) in 51 cases on LCD is shown in Fig. 8. In four 
groups, cases with extremely high values were observed in 
group C, and the levels were almost same in groups A, B 
and D.
Fig. 9 shows the value and ratio of 3-OHBA. Its value 
was from normal values to 3,577 μmol/mL, and the ratio 
was around 60% to 70% when the values were within the
standard and three fold levels (less than 85 μmol/mL and
255 μmol/mL). As 3-OHBA level increases, its ratio increases
approximately up to 90%.
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Table 1. Base data of the patients.
1) Fasting values
Fasting glucose 
HbA1c 　　　　 
IRI　　　　　 
Triglyceride　　 
HOMA-R 　　　 
HOMA-β 　　 
161.7
212.4
50.8
8.5
22.7
14.2
 0.39
51.6 mg/dL
60.9 mg/dL 
25.8 mg/dL
4.9 μU/mL
15.0 μU/mL
12.7 μU/mL
0.38
±
±
±
±
±
±
±
2) Meal loading (carbohydrate 70 g)
Glucose (0 min) 
Glucose (30 min) 　　　　 
Glucose (increase)　　　　　 
 IRI    (0 min)　　 
 IRI    (30 min)　　　 
 IRI    (increase)
 IGI-carbo70　　 
IRI, immunoreactive insulin; HOMA, homeostasis model assessment; IGI-carbo70, 
insulinogenic index-70 g of carbohydrate in calorie-restricted (CR) diet. Data are 
shown in mean ± standard deviation. 
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Fig. 2. HOMA-R and HOMA-β of the patients.
As for HOMA-R, the normal range is usually under 1.6 and a value more than 2.5 suggests the presence of insulin 
resistance (n = 24). As for HOMA-β, the normal range is from 40 to 60 (n = 24). Bar indicates standard deviation. 
HOMA, homeostasis model assessment.
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Fig. 4. Serum triglyceride level in fasting on day two and day 12. 
The patients were on calorie-restricted diet (CR) with carbohydrate ratio 60 % 1,400 kcal/day in day zero to two, and on low 
carbohydrate diet (LCD) with carbohydrate ratio 12 %, 1,400 kcal/day on day three to13. The average value of TG decreased 
from 233.9 ± 324.6 mg/dL to 110.3 ± 69.3 mg/dL (mean ± SD), with a significant difference (p < 0.01), when two cases were 
included (a: n = 1,372, b: n = 1,267). When we exclude two cases, TG value decreased from 143.4 ± 86.8 mg/dL to 93.9 ± 
34.8 mg/dL (mean ± SD), with significant difference ( ＊ : p < 0.01). TG, triglyceride; SD, standard deviation.
Fig. 3. Blood glucose values after zero min and 120 min for breakfast on day two and day 12.
The subjects were on a calorie restriction diet (CR) on days zero to two (n = 24), and on a low carbohydrate diet 
(LCD) on day three to13 (n = 24). Both regimen had same calories of 450 kcal. Bar indicates standard deviation.
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Fig. 6. A trial for calculating insulinogenic index (IGI) for meals including 70g of carbohydrate.
As the same concept for IGI in 75 g oral glucose tolerance tests (75g OGTT), insulinogenic index-carbo70 (IGI-
carbo70) is calculated in order to speculate the ability of insulin. IGI-carbo70 was 0.39 ± 0.38 in mean ± SD, and 0.39 
± 0.08 in mean ± SEM (n = 20). OGTT, oral glucose tolerance test; SD, standard deviation; SEM, standard error mean.
Fig. 5. Responses of glucose against meals including 70 g of carbohydrate.
The responses of glucose and IRI were from 161.7 ± 51.6 mg/dL to 212.4 ± 60.9 mg/dL, and from 8.5 ± 4.9 μU/mL 
to 22.7 ± 15.0 μU/mL, respectively (n = 22). IRI, immunoreactive insulin.
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Fig. 7. Correlation among HbA1c, HOMA-R, HOMA-β, IRI (fasting, increase, 30 min) and blood glucose (n = 24).
a: Correlation between HbA1c and HOMA-R, not significant.
b: Correlation between HbA1c and HOMA-β, significant, p < 0.01.
c: Correlation between fasting IRI and fasting glucose, significant, p < 0.05.
d: Correlation between fasting IRI and HOMA-β, significant, p < 0.01.
e: Correlation between IRI increase and HOMA-R, not significant.
f: Correlation between IRI increase and HOMA-β, significant, p < 0.05.
g: Correlation between IRI in 30 min. and HOMA-R, significant, p < 0.05.
h: Correlation between IRI in 30 min. and HOMA-β, significant, p < 0.001.
HOMA, homeostasis model assessment; IRI, immunoreactive insulin.
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Fig. 8. The value of blood ketone bodies in 51 cases on LCD. 
According to continuing days on LCD, we classified four groups, in which group A is four to five days (n = 4), B is seven to nine days (n = 5), 
C is 11 to 13 days (n = 21), D is 21 to 28 days (n = 21). Cases with extremely high value were observed in group C, and the levels were almost 
same in group A, B and D. LCD, low carbohydrate diet. Bar indicates standard deviation.
Fig. 9. Correlation between 3-OHBA value in blood and 3-OHBA ratio in ketone bodies (n = 39).
When 3-OHBA value is within the standard level and its three fold level (less than 85 μmol/mL and 255 μmol/mL) the 3-OHBA ratio in 
ketone bodies are around 60 % to 70 %. As 3-OHBA values increase, the ratio of 3-OHBA increases up to approximately 90 %. 3-OHBA, 
3-hydroxybutylic acid.
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Discussion
1) Long effects of LCD   
Our coworkers and we have continued to develop 
clinical studies and research of LCD for many years 9-13).  
The degree of weight reduction seemed to be satisfactory 
(Fig. 1). Weight check-up after LCD intervention was 
measured when the weight became stable in six to 12 months. 
The diet protocol was started on super-LCD (carbohydrate 
12%, avoiding staple food such as rice and bread in 
three meals), and after the standard-LCD (carbohydrate 
24%, avoiding staple food in two meals) and petit-LCD 
(carbohydrate 36%, avoiding staple food in one meal) were 
applied, depending on the situation of the patients, which 
can reduce the weight gain rebound 9-12). Reports with more 
than 2,000 cases have been rare, and our results would be 
fundamental data in light of ordinary outpatient care.
Through our investigation, we can suggest several 
characteristic aspects, such as 1) adequate education of meals
and daily life, 2) behavioral changes in the most patients, 3) 
spontaneous continuation of LCD after the research protocol, 
4) wide spread of LCD by recommendation of the patient for 
his or her family and acquaintances and 5) social information 
and recognition of short and long term effects of LCD.
2) Weight reduction of LCD   
 Our results could be compared with recent reports for 
LCD. Randomized controlled trials (RCTs) have consistently 
shown that LCD reduces body weight, with mean reductions 
ranging from 2.1 to 14.3 kg over at least six months of 
intervention 14).
Weight reduction between CR and LCD showed that 
7.4% versus 9.0% in 227 cases 15), and 1.5 kg versus 5.3 kg 
in 148 cases one year later 16). From 53 reports with 68,128 
cases, the long-term effects depend on the intensity of the 
intervention 17). On the contrary, meta-analysis of 19 papers 
of 3,209 cases revealed no significant difference of weight 
reduction in LCD and other diets 18). 
Compared with these reports, our result would be 
successful particularly because weight reduction for LCD 
was remarkable in the cases, reducing more than 10% in 
25.6%, and more than 5% in 57.6%. 
3) International comparison of LCD   
 In Japan, our methods for LCD have been utilized and 
prevalent in clinical practice for years because of simple 
and easy to understand the content. Three types and ratios 
of carbohydrates were super-LCD without three staple foods 
(12%), standard-LCD without two staple foods (22% - 25%) 
and petit - LCD without one staple food (35% - 40%). 
The content of LCD can be compared with the 
international situation of LCD. Recently, Bernstein and 
Feinman et al 19) suggested definitions and related comments 
of LCD as follows: 1) Very low-carbohydrate ketogenic 
diet (VLCKD): Carbohydrate, 20 to 50 g/day or <10% of 
the 2,000 kcal/day diet. 2) Low-carbohydrate diet: <130 g/
day or <26% total energy. The ADA definition of 130 g/day 
is its recommended minimum. 3) Moderate-Carbohydrate 
Diet: 26% to 45%. Upper limit, approximate carbohydrate 
intake before the obesity epidemic (43%). 
4) High-Carbohydrate Diet: >45%   
 Despite the differences in weight change on diets, LCD 
resulted in similar or greater improvement in inflammation, 
adipocyte dysfunction, and endothelial dysfunction than a 
standard low-fat diet among obese persons. 
In the light of appellation, LCD and CR have been used 
for a long time, but recently, new and different terms have been
used. They are high fat, low carbohydrate (HFLC) diet; low
fat, high carbohydrate (LFHC) diet 20); very low-carbohydrate
ketogenic diet (VLCKD); low fat diet (LFD) 21-23); higher-
protein (HP) diet (38% carbohydrate, 30% protein, 29% 
fat);higher-carbohydrate diet 24); and low carbohydrate (120 g 
carbohydrates/day) and low fat diets (30% energy from fat/
day) 25).
Consequently, our three types of LCDs seem to be 
equivalent as follows: Super-LCD is equivalent to 1) VLCKD,
standard-LCD to 2) LCD and petit-LCD to 3) Moderate-
Carbohydrate Diet. In actual medical practices of diabetes, 
we have adapted three types of LCDs to each patient with 
adequate situations. 
5) Short-term effects of glucose and TG   
 TG levels showed rapid and significant decreases 
through super-LCD for ten days from 143.4 ± 91.4 mg/dL
to 93.9 ± 34.8 mg/dL. It is well known that LCD makes TG
decrease in former studies. RCT of 23 reports until 36 months
with 29.7 mg/dL decrease 26), RCT of 227 cases at 12 months 
with 37 mg/dL decrease 15), meal of carbohydrate less than 
40 g/day for 12 months with a 14.1 mg/dL decrease 27), 
lack of supple meals (rice) one to two times per day for six 
months with 16 mg/dL decrease 28), LCD including 43% of 
carbohydrate with 14.9 mg/dL decrease for five weeks 29) and 
Atkin’s method for 14 days with TG decrease from 154 mg/
dL to 89.9 mg/dL 30, 31) which is similar to our result.
As for human research of LCD for six to 12 months, 
there is a limitation in research design because subjects 
have meals at home. In contrast, our design was performed 
that the patients were admitted and examined with super-
LCD including carbohydrates of 12%, suggesting higher 
reliability and significance of LCD research. 
6) Trial for IGI-carbo70   
To speculate the function of pancreatic beta cells, 
insulinogenic index (IGI) analysis in 75g OGTT has been
used until now 32-34). However, IGI is not so applied to diabetic
patients already diagnosed, because of rapid hyperglycemia. 
Current study includes blood glucose and insulin values 
on 0 and 30 minutes after breakfast including carbohydrate 
70 g. From these data, we calculated and showed “insulinogenic
index-carbo70 (IGI-carbo70)” in Figs. 5 and 6, because of 
almost same weight of glucose. 
As a reference, there is a report of hyperglycemia due to 
a bowl of rice topped with beef (gyudon) 35). Twelve healthy
subjects were given three test foods, which were steamed 
rice (230 g), “gyudon” with or without ginger (15 g), including
78 g, 82.9 g, and 83.5 g of carbohydrates each. Blood glucose
was elevated by 65 to 75 mg/dL after 30 min, and details 
were investigated in light of the area under the curve (AUC) 
of glucose increments.
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From these data, it is noteworthy that even normal 
subjects have hyperglycemia against 80 g of carbohydrate in 
food, and that postprandial research of glucose and insulin 
would be useful and important. In Fig. 6, 3/4 of cases of 
IGI-carbo70 were less than 0.5, suggesting a possible useful 
marker in the future. 
7) HOMA-R and HOMA-β   
 As for mutual correlations, higher HbA1c suggests 
lower HOMA-β, indicating decreased secretion ability 
(Figs. 7a, b). Glucose profile seems to be influenced with 
factors such as obesity, insulin resistance, secretion ability, 
and mean amplitude of glycemic excursions (MAGE) (Figs. 
7c, d ). Increased IRI value indicating of insulin secretion 
ability showed no significant correlation with HOMA-R, 
suggesting less of a relationship with insulin resistance 
(Figs. 7e, f ).
It is known that IRI values in 120 min for 75g OGTT 
correlates with the level of HOMA-β, which is compatible 
with the significant correlation with p < 0.001 (Fig. 7h). 
HOMA-R showed a significant correlation with IRI values in 
120 min without a significant correlation with IRI increase 
(Figs. 7e, g), suggesting elevated fundamental IRI values, 
due to insulin resistance.
HOMA-R and HOMA-β were applied to the evaluation 
for insulin resistance and secretion, in which reliability would
be increased when fasting glucose is less than 140 mg/dL
and 130 mg/dL, respectively. Consequently, there are possible
fluctuations of reliability that the former has rather decreased,
and the latter has rather increased. As for the limitation of the
research design, further investigation would be necessary.
HOMA-R and HOMA-β were originally proposed by 
Matthews et al 36), and have been used widely and highly 
estimated. Recent development includes using C-peptide 
values alternatively 37), and newly trials for iHOMA2 38), 
expecting further useful analysis methods. 
8) Ketone bodies and LCD   
 Hyperketonemia has usually been classified as 1) 
diabetic ketoacidosis (DKA) and 2) physiological ketosis. The
former shows that blood sugar is more than 300 mg/dL with 
acidosis, and ketone bodies are 20 to 25 mmol/L 21, 39). As for 
the report of DKA 19 cases, average values are as follows: 
glucose 650 mg/dL, pH 7.13, T-ketone 10.2 ± 1.8 mmol/L, 
and acetoacetic acid (AcAc) 2.7 ± 0.5 mmol/L, 3-OHBA 7.5 
± 1.3 mmol/L, the ratio of 3-OHBA 74% 40).
On the contrary, the latter shows that blood glucose is in 
a normal range and plasma ketone body levels increase six 
to eight mM during a prolonged fast without giving rise to 
clinically hazardous acidosis 21). The cause is usually from 
starvation and a ketogenic diet, and was proposed by the 
famous biochemist Crebs, who was given the Nobel Prize 41).
In our study (Figs. 8, 9), we started diet therapy as 
super-LCD that has 1,400 kcal/day, 12% carbohydrates and
42 g of carbohydrates per day. Blood values of ketone bodies
were 160 to 4,000 μmol/L (0.16 to 4 mmol/L) in Fig. 8, and 
that of 3-OHBA was 136 to 3,577 μmol/L (0.14 to 3.58 
mmol/L) in Fig. 9. Our data would be compared with similar 
situations of previous reports.
The blood values of a healthy person are 72 to 90 mg/
dL of glucose and less than 0.2 mmol/L of ketone bodies. 
Fasting increases blood ketone bodies, and 3-OHBA levels 
after fasting are 0.3 to 0.5 mmol/L in 24 hours, one to two 
mmol/L in two to three days, three mmol/L in three to four 
days 42) and four to five mmol/L in seven to ten days.  
When patients with obesity continue fasting for 40 days, 
they would not show acidosis and their 3-OHBA values 
are six to eight mmol/L with the ratio of 3-OHBA at about 
78% 43).
During fasting, giving 150 g of glucose per day for 
seven days would make 3-OHBA less than 0.5 mmol/L. In 
contrast, discontinuing glucose administration would result 
in elevated 3-OHBA, with 4.3 mM in ten days and 4.8 mM 
in 12 days 42). Glucose intake of 20 to 40 g is associated with 
3-OHBA of approximately one mM, but wide variations 
exist between people 42).
From several comparisons of previous reports, we 
can compare 3-OHBA value in three to four days, where 
three mmol/L in fasting 42) versus 0.36 mmol/L in 42 g of 
carbohydrate for super-LCD (Fig. 8). Furthermore, we can 
compare the ratio of 3-OHBA in ketone bodies, where 
approximately 78% in six to eight mmol/L of ketone bodies 
due to continuous fasting 43) versus about 60% to 90% in 
0.1 to three mmol/L due to LCD (Fig. 9). These data would 
be the fundamental data in the research concerning ketone 
bodies.
Conclusion 
We have continued clinical studies and research of LCD 
for many years. These studies revealed that for 1) long–term 
effects; weight reduction more than 10% was 25.6%, more 
than 2.5% was 78.8% in 2,699 cases, 2) short-term effects; 
blood glucose and triglyceride values decreased significantly 
in 10 days, 3) ketone bodies and 3-OHBA were elevated due 
to super-LCD meals from four to five days. These findings 
are fundamental data in the LCD area and contribute the 
research of glycative changes.
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